miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We have recently identified down-regulated microRNAs including miR-145 and miR-133a in bladder cancer (BC). The aim of this study is to determine the genes targeted by miR-145, which is the most down-regulated microRNA in BC. METHODS: We focused on fascin homologue 1 (FSCN1) from the gene expression profile in miR-145 transfectant. The luciferase assay was used to confirm the actual binding sites of FSCN1 mRNA. Cell viability was evaluated by cell growth, wound-healing, and matrigel invasion assays. BC specimens were subjected to immunohistochemistry of FSCN1 and in situ hybridisation of miR-145. RESULTS: The miR-133a as well as miR-145 had the target sequence of FSCN1 mRNA by the database search, and both microRNAs repressed the mRNA and protein expression of FSCN1. The luciferase assay revealed that miR-145 and miR-133a were directly bound to FSCN1 mRNA. Cell viability was significantly inhibited in miR-145, miR-133a, and si-FSCN1 transfectants. In situ hybridisation revealed that miR-145 expression was markedly repressed in the tumour lesion in which FSCN1 was strongly stained. The immunohistochemical score of FSCN1 in invasive BC (n=46) was significantly higher than in non-invasive BC (n=20) (P=0.0055). CONCLUSION: Tumour suppressive miR-145 and miR-133a directly control oncogenic FSCN1 in BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956 · cited 1×
“MicroRNAs are an abundant class of small non-coding RNAs of about 22 nucleotides in length that function as negative regulators of gene expression through antisense complimentarily to specific messenger RNAs (Lagos-Quintana et al, 2001).”
BackgroundBandrés, E., Cubedo, E., Agirre, X., Malumbres, R., Zárate, R., Ramírez, N., Abajo, A., Navarro, A., Moreno, I., Monzó, M., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-29 · Cited by 884
p53 represses c-Myc through induction of the tumor suppressor miR-145
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., & Mo, Y.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808042106 · Cited by 841
Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue
Wong, T.-S., Liu, X.-B., Wong, B. Y.-H., Ng, R. W.-M., Yuen, A. P.-W., & Wei, W. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0666 · Cited by 750
Wang, X., Tang, S., Le, S.-Y., Lu, R., Rader, J. S., Meyers, C., & Zheng, Z.-M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002557 · Cited by 741
International Union Against Cancer (UICC)
Turner, B. (2012) · The Statesman’s Yearbook · doi:10.1007/978-1-349-59541-9_43 · Cited by 720
Cited by
Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)
ALLEGRA, A., ALONCI, A., CAMPO, S., PENNA, G., PETRUNGARO, A., GERACE, D., & MUSOLINO, C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1647 · Cited by 359
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis
Xu, Q., Liu, L.-Z., Qian, X., Chen, Q., Jiang, Y., Li, D., Lai, L., & Jiang, B.-H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr730 · Cited by 284
The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
Yoshino, H., Chiyomaru, T., Enokida, H., Kawakami, K., Tatarano, S., Nishiyama, K., Nohata, N., Seki, N., & Nakagawa, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.23 · Cited by 273
Self-citationlincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6
Eades, G., Wolfson, B., Zhang, Y., Li, Q., Yao, Y., & Zhou, Q. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0251 · Cited by 271
Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR
Chiyomaru, T., Yamamura, S., Fukuhara, S., Yoshino, H., Kinoshita, T., Majid, S., Saini, S., Chang, I., Tanaka, Y., Enokida, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070372 · Cited by 266
Self-citationAbdollahzadeh, R., Daraei, A., Mansoori, Y., Sepahvand, M., Amoli, M. M., & Tavakkoly‐Bazzaz, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27941 · Cited by 261
microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers
Nohata, N., Hanazawa, T., Enokida, H., & Seki, N. (2012) · Oncotarget · doi:10.18632/oncotarget.424 · Cited by 253
Self-citationSUZUKI, S., YOKOBORI, T., TANAKA, N., SAKAI, M., SANO, A., INOSE, T., SOHDA, M., NAKAJIMA, M., MIYAZAKI, T., KATO, H., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1831 · Cited by 100
“Transfection of miR-133a induced reductions in cell proliferation, migration and invasion (25).”
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
Metadata
- Authors
- Chiyomaru, T., Enokida, H., Tatarano, S., Kawahara, K., Uchida, Y., Nishiyama, K., Fujimura, L., Kikkawa, N., Seki, N., & Nakagawa, M.
- Venue
- British Journal of Cancer
- Published
- 2010-02-16
- Volume
- 102
- Issue
- 5
- Pages
- 883-891
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2114557056
- Cited by
- 325
- References
- 45
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.